RxDoctor Payments Data

Jarred Uhrig

Acute Care · Wilmington, OHNPI 1245839844

Payments from drug & device makers

$1,147in general payments, 2019–2025

Across 67 payments — averaging $17.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$381
  • Amgen$254
  • Novartis$201
  • Boehringer Ingelheim$123
  • Philips North America LLC$48
  • Esperion Therapeutics, Inc.$46
  • plus $94 from 4 others

What the payments were for

  • Food & beverage$1,04791%
  • Education$1009%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,147 in reported general payments places this provider in the 75th percentile of 1,101 acute care providers in Ohio.

See all acute care providers in Ohio

Medicare billing

Part B allowed, 2024
$67,776
Medicare patients
377
Services billed
728

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban312$329,420
EntrestoSacubitril/Valsartan228$235,007
XareltoRivaroxaban84$83,763
JardianceEmpagliflozin68$69,958
FarxigaDapagliflozin Propanediol62$59,595
BrilintaTicagrelor69$51,934
Repatha SyringeEvolocumab23$18,277
Repatha SureclickEvolocumab11$9,503
VascepaIcosapent Ethyl13$5,230
Metoprolol Succinate344$3,896
Ranolazine ErRanolazine35$3,310
Atorvastatin Calcium399$3,150
Isosorbide Mononitrate ErIsosorbide Mononitrate229$3,118
ClopidogrelClopidogrel Bisulfate295$2,184
Losartan Potassium260$2,121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$19$329,420312 claims
NovartisEntresto$201$235,007228 claims
AstraZenecaFarxiga, Brilinta$381$111,529131 claims
Johnson & JohnsonXarelto$15$83,76384 claims
Boehringer IngelheimJardiance$123$69,95868 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,101 acute care providers in Ohio.

Other acute care in Wilmington

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →